|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Fusion of the Platelet-Derived Growth Factor Receptor  to a Novel Gene CEV14 in Acute Myelogenous Leukemia After Clonal Evolution
Akihiro Abe,
Nobuhiko Emi,
Mitsune Tanimoto,
Hiroshi Terasaki,
Toru Marunouchi, and
Hidehiko Saito
From the First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya; Mitsubishi Bioclinical Laboratory Inc, Tokyo; the Division of Cell Biology, Fujita Health University, Aichi; and Aichi Juridical Foundation for Blood Disease Research, Nagoya, Japan.
Chromosomal translocations involving band 5q31-35 occur in several hematologic disorders. A clone with a t(5; 14)(q33; q32) translocation appeared at the relapse phase in a patient with acute myelogenous leukemia who exhibited a sole chromosomal translocation, t(7; 11), at initial diagnosis. After the appearance of this clone, the leukemia progressed with marked eosinophilia, and combination chemotherapy was ineffective. Southern blot analysis showed a rearrangement of the platelet-derived growth factor receptor  (PDGFR) gene at 5q33 which was not observed at initial diagnosis. This translocation resulted in a chimeric transcript fusing the PDGFR gene on 5q33 with a novel gene, CEV14, located at 14q32. Expression of the 5' region of the PDGFR cDNA, upstream of the breakpoint, was not detected. However, the 3' region of PDGFR, which was transcribed as part of the CEV14-PDGFR fusion gene, was detected. A partial cDNA for a novel gene, CEV14, includes a leucine zipper motif and putative thyroid hormone receptor interacting domain and is expressed in a wide range of tissues. The expression of a CEV14-PDGFR fusion gene in association with aggressive leukemia progression suggests that this protein has oncogenic potential.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4271-4277
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al.
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene
Haematologica,
February 1, 2007;
92(2):
163 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc.,
April 1, 2006;
81(4):
553 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol.,
September 10, 2005;
23(26):
6285 - 6295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Delaval, S. Letard, H. Lelievre, V. Chevrier, L. Daviet, P. Dubreuil, and D. Birnbaum
Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome
Cancer Res.,
August 15, 2005;
65(16):
7231 - 7240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc.,
July 1, 2005;
80(7):
947 - 958.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood,
January 1, 2005;
105(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gillingham, A. H. Y. Tong, C. Boone, and S. Munro
The GTPase Arf1p and the ER to Golgi cargo receptor Erv14p cooperate to recruit the golgin Rud3p to the cis-Golgi
J. Cell Biol.,
October 25, 2004;
167(2):
281 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani and A. Tefferi
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Blood,
October 1, 2004;
104(7):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Morerio, M. Acquila, C. Rosanda, A. Rapella, C. Dufour, F. Locatelli, E. Maserati, F. Pasquali, and C. Panarello
HCMOGT-1 Is a Novel Fusion Partner to PDGFRB in Juvenile Myelomonocytic Leukemia with t(5;17)(q33;p11.2)
Cancer Res.,
April 15, 2004;
64(8):
2649 - 2651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Vizmanos, F. J. Novo, J. P. Roman, E. J. Baxter, I. Lahortiga, M. J. Larrayoz, M. D. Odero, P. Giraldo, M. J. Calasanz, and N. C. P. Cross
NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder1
Cancer Res.,
April 15, 2004;
64(8):
2673 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wilkinson, E. R. P. Velloso, L. F. Lopes, C. Lee, J. C. Aster, M. A. Shipp, and R. C. T. Aguiar
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib
Blood,
December 1, 2003;
102(12):
4187 - 4190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Griffin, J. Leung, R. J. Bruner, M. A. Caligiuri, and R. Briesewitz
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
PNAS,
June 24, 2003;
100(13):
7830 - 7835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gillingham, A. C. Pfeifer, and S. Munro
CASP, the Alternatively Spliced Product of the Gene Encoding the CCAAT-Displacement Protein Transcription Factor, Is a Golgi Membrane Protein Related to Giantin
Mol. Biol. Cell,
November 1, 2002;
13(11):
3761 - 3774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Magnusson, K. E. Meade, K. E. Brown, D. C. Arthur, L. A. Krueger, A. J. Barrett, and C. E. Dunbar
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor {beta} receptor in chronic myelomonocytic leukemia
Blood,
October 15, 2001;
98(8):
2518 - 2525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schwaller, E. Anastasiadou, D. Cain, J. Kutok, S. Wojiski, I. R. Williams, R. LaStarza, B. Crescenzi, D. W. Sternberg, P. Andreasson, et al.
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor {beta} gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
Blood,
June 15, 2001;
97(12):
3910 - 3918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kuno, A. Abe, N. Emi, M. Iida, T. Yokozawa, M. Towatari, M. Tanimoto, and H. Saito
Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)
Blood,
February 15, 2001;
97(4):
1050 - 1055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kulkarni, C. Heath, S. Parker, A. Chase, S. Iqbal, C. F. Pocock, J. Kaeda, K. Cwynarski, J. M. Goldman, and N. C. P. Cross
Fusion of H4/D10S170 to the Platelet-derived Growth Factor Receptor {beta} in BCR-ABL-negative Myeloproliferative Disorders with a t(5;10)(q33;q21)
Cancer Res.,
July 1, 2000;
60(13):
3592 - 3598.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Infante, F. Ramos-Morales, C. Fedriani, M. Bornens, and R. M. Rios
GMAP-210, A Cis-Golgi Network-associated Protein, Is a Minus End Microtubule-binding Protein
J. Cell Biol.,
April 5, 1999;
145(1):
83 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Ross, O. A. Bernard, R. Berger, and D. G. Gilliland
Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor beta Receptor (PDGFbeta R) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2)
Blood,
June 15, 1998;
91(12):
4419 - 4426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Saint-Dic, S. C. Chang, G. S. Taylor, M. M. Provot, and T. S. Ross
Regulation of the Src Homology 2-containing Inositol 5-Phosphatase SHIP1 in HIP1/PDGFbeta R-transformed Cells
J. Biol. Chem.,
June 8, 2001;
276(24):
21192 - 21198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
